Skip to content

Concussion Testing: A Novel Non-invasive Concussion Detection Device

Concussion Testing: A Novel Non-invasive Concussion Detection Device

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02370914
Enrollment
84
Registered
2015-02-25
Start date
2011-08-31
Completion date
2011-12-31
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Concussion

Keywords

Concussion

Brief summary

The purpose of this study is to establish and evaluate a distinctive signal for concussion.

Detailed description

The purpose of this study is to establish a non-invasive objective measurement for the detection of concussions with the Jan Medical Device (JMD). The study will assess the ability of this device to demonstrate unique signals that correlate with concussions. The study will also test the athletes at baseline at rest and during exertion to determine if there is a difference in the signal from exertion alone. The JMD is a non-invasive band that is placed around the participants head. The JMD detects a unique pattern of signals based on displacement of the skull from changes in blood flow during individual heartbeats. The athletes will be tested longitudinally to assess to changes over time, in addition to changes after impact

Interventions

Recording of subjects with Nautilus NeuroWave diagnostic device

BEHAVIORALSCAT

A Neurocognitive evaluation of the patients to assess for concussion.

Sponsors

Jan Medical, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
14 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* Junior Varsity and Varsity Players a local High School.

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
A Measure Assessing the Sensitivity and Specificity Rate Based on the Nautilus Neurowave DataIndividual assessments were made within 2 days of recordingSensitivity (also called the true positive rate) measures the proportion of concussed participants that are correctly identified as such by utilizing the information within the Nautilus Neurowave data. Specificity (also called the true negative rate) measures the proportion of non-concussed participants that are correctly identified as such by utilizing the information within the Nautilus Neurowave data The information that is evaluated from within this data is recognized through the computation of two parameters, R1 and R2. Both R1 and R2 are measured by computing the frequency spectrum using an FFT of the Neurowave data and computing a ratio of the signal intensities at specific higher frequencies against specific lower frequencies within that spectrum. Based on this computation, the recorded data is evaluated as coming from a concussed participant if R1 \>= 1.0 and R2 \>= 0.66 and is considered non-concussed otherwise.

Countries

United States

Participant flow

Participants by arm

ArmCount
Diagnostic Device - Nautilus NeuroWave
Nautilus NeuroWave diagnostic device. Recordings were evaluated by a Jan Medical concussion algorithm . Nautilus NeuroWaveTM System: Recording of subjects with Nautilus NeuroWave diagnostic device
82
Total82

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyProtocol Violation2

Baseline characteristics

CharacteristicDiagnostic Device - Nautilus NeuroWave
Age, Categorical
<=18 years
80 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
2 Participants
Age, Continuous15.3 years
STANDARD_DEVIATION 1.33
Region of Enrollment
United States
82 participants
Sex/Gender, Customized
Males
82 participants
Sport Concussion Assessment Tool- Second Edition (SCAT 2)82.5 units on a scale
STANDARD_DEVIATION 10.2

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 82
serious
Total, serious adverse events
0 / 82

Outcome results

Primary

A Measure Assessing the Sensitivity and Specificity Rate Based on the Nautilus Neurowave Data

Sensitivity (also called the true positive rate) measures the proportion of concussed participants that are correctly identified as such by utilizing the information within the Nautilus Neurowave data. Specificity (also called the true negative rate) measures the proportion of non-concussed participants that are correctly identified as such by utilizing the information within the Nautilus Neurowave data The information that is evaluated from within this data is recognized through the computation of two parameters, R1 and R2. Both R1 and R2 are measured by computing the frequency spectrum using an FFT of the Neurowave data and computing a ratio of the signal intensities at specific higher frequencies against specific lower frequencies within that spectrum. Based on this computation, the recorded data is evaluated as coming from a concussed participant if R1 \>= 1.0 and R2 \>= 0.66 and is considered non-concussed otherwise.

Time frame: Individual assessments were made within 2 days of recording

Population: Analysis population includes all participants. Some of these participants were were declared concussed by the physician in the team during the course of the season. All baseline recordings were treated as from non-concussed participants.

ArmMeasureGroupValue (NUMBER)
Diagnostic Device - Nautilus NeuroWaveA Measure Assessing the Sensitivity and Specificity Rate Based on the Nautilus Neurowave DataSensitivity77 percentage of participants
Diagnostic Device - Nautilus NeuroWaveA Measure Assessing the Sensitivity and Specificity Rate Based on the Nautilus Neurowave DataSpecificity87 percentage of participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026